MOST试验中电子知情同意的应用与招募影响
本研究为MOST(多臂优化卒中溶栓试验)的事后分析,2019年10月10日至2023年7月5日在美国57个中心纳入514例受试者,比较纸质与电子知情同意(eConsent)的使用情况。结果显示eConsent用于173例(33.7%),使用eConsent的中心入组量更高,远程同意比例更高,且同意文书依从性优于纸质同意。
要点
- eConsent用于514例中的173例(33.7%),57个中心中32个(56.1%)至少使用一次。
- 使用eConsent的中心入组中位数高于未使用中心(7.5 vs 3,P<0.001)。
- eConsent较纸质同意更多采用远程方式(46.2% vs 1.2%,P<0.001)。
核心结论
- MOST中eConsent与更高的单中心入组量、更高的远程同意率及更好的同意文书依从性相关。
- 研究概述了eConsent在未来急性缺血性卒中临床试验和卒中研究网络中可能具有的优势。
研究设计与样本
- MOST为III期急性缺血性卒中临床试验,本文为其eConsent采用情况的事后分析。
- 2019年10月10日至2023年7月5日在美国57个中心纳入514例受试者。
- 各中心每次入组可选用纸质同意或eConsent,研究数据库用于判定每例受试者的同意方式(纸质现场、纸质远程、eConsent现场、eConsent远程)。
- 采用描述性统计报告eConsent采用趋势和受试者人口学多样性,并用χ2和Kruskal-Wallis检验进行比较。
主要发现
- 514例中173例(33.7%)使用eConsent。
- 57个中心中32个(56.1%)至少使用一次eConsent,这些中心整个试验期间的入组中位数高于未使用eConsent的中心(7.5[四分位距5-17] vs 3[四分位距2-4];P<0.001)。
- eConsent完成远程同意的比例高于纸质同意(46.2% vs 1.2%;P<0.001)。
- eConsent现场组与纸质现场组的受试者人口学多样性和基线神经影像至随机化时间相似(中位数58.5[四分位距46.5-72.5] vs 55[四分位距39-70]分钟)。
- eConsent现场的同意文书依从性优于纸质现场,包括每100例受试者的数据澄清请求更少(44 vs 81)和可报告的非预期事件更少(6 vs 25)。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obtaining timely informed consent is a key barrier in acute ischemic stroke clinical trial recruitment. Electronic consent (eConsent) allows electronic delivery and documentation of the informed consent process, which may optimize recruitment. eConsent in acute ischemic stroke clinical trials, however, is limited and understudied. We conducted a post hoc analysis of eConsent adoption in MOST (Multi-Arm Optimization of Stroke Thrombolysis Trial), a phase III acute ischemic stroke clinical trial, and studied the impact on recruitment. METHODS: From October 10, 2019, to July 5, 2023, MOST enrolled 514 participants at 57 sites in the United States. Study databases were reviewed to determine informed consent modality for each participant: paper-in person, paper-remote, eConsent-in person, and eConsent-remote. Study sites could use paper consent or eConsent for each enrollment. eConsent adoption trends and participant demographic diversity were reported using descriptive statistics. We utilized χ2 and Kruskal-Wallis tests to compare individual site enrollment, remote consent utilization, baseline neuroimaging-to-randomization times, data clarification requests, and reportable consent-related unanticipated events. RESULTS: eConsent was utilized for 173 (33.7%) of 514 participants. Of 57 sites, 32 (56.1%) utilized eConsent at least once: those sites had higher median enrollment over the course of the entire trial than non-eConsent sites (7.5 [interquartile range, 5-17] versus 3 [interquartile range, 2-4]; P<0.001). eConsent was completed remotely more frequently than paper consent (46.2% versus 1.2%; P<0.001). Participant demographic diversity and baseline neuroimaging-to-randomization times were similar between eConsent-in person and paper-in person (median, 58.5 [interquartile range, 46.5-72.5] versus 55 [interquartile range, 39-70] minutes). Consent documentation adherence was superior with eConsent-in person compared with paper-in person including decreased data clarification requests (44 versus 81 per 100 participants) and reportable unanticipated events (6 versus 25 per 100 participants). CONCLUSIONS: eConsent in MOST was associated with higher individual site enrollment, higher remote consent rates, and improved consent documentation adherence over paper consent. Our study outlines the potential advantages of eConsent adoption in future acute ischemic stroke clinical trials and stroke research networks.
引用
- Davis SI, Staugaitis A, Rines I, et al. Electronic Informed Consent in the Multi-Arm Optimization of Stroke Thrombolysis Trial. Stroke. 2025. PMID: 40235446. doi:10.1161/STROKEAHA.124.049369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。